- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01461577
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)
January 29, 2013 updated by: Sanofi
A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure
Primary Objective:
- To assess the efficacy of insulin glargine as measured by changes of HbA1c levels from baseline in type 2 diabetes mellitus (T2DM) patients following GLP-1 failure.
Secondary Objective:
- To determine the change in glycemic control, safety, and treatment satisfaction in insulin glargine use in patients following GLP-1 failure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
1-2 weeks screening period, 24 weeks treatment period, 1 week follow-up period
Study Type
Interventional
Enrollment (Actual)
89
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patients of aged ≥30 and ≤75 years with type 2 diabetes mellitus (T2DM)
- Hemoglobin A1c (glycosylated hemoglobin; HbA1c) levels measured at screening ≥7.5%
- Continuous treatment with stable doses of GLP-1 analogue for >3 months prior to enrollment (for patients also using oral anti-hyperglycemic drugs [OADs], continuous treatment with stable doses of OADs for >3 months prior to enrollment)
Exclusion criteria:
- Inpatient with T2DM
- Diabetes other than T2DM (e.g. secondary to pancreatic disorders, drug or chemical agent intake)
- Fasting plasma glucose (FPG) levels <130mg/dL
- Body mass index (BMI) >28 kg/m2
- Patients using thiazolidinediones in the last 3 months prior to enrollment
- Use of any treatment for weight loss in the last 3 months prior to enrollment
- Treatment with systemic corticosteroids within the 3 months prior to enrollment
- Patients using non-selective ß-blockers
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol
- Most recent ophthalmologic examination >6 months prior to enrollment
- Diabetic retinopathy with surgical treatment (last photocoagulation or vitrectomy) in the 3 months before enrollment or which may require surgical treatment
- Proliferative diabetic retinopathy or any other unstable rapidly progressive retinopathy
- Impaired renal function defined as, but not limited to, serum creatinine ≥1.3 mg/dL [males] or ≥1.2 mg/dL [females] or presence of macroproteinuria (>1 g/day)
- Active liver disease including hepatic cirrhosis, hepatic failure, and hepatitis or alanine transaminase (ALT) or aspartate aminotransferase (AST) >2 times upper limit or total bilirubin >1.5 times upper limit of normal (except in case of Gilbert's syndrome) at enrollment
- Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol
- Any medical condition that may have an influence on HbA1c rate
- Currently undergoing therapy for malignancy which may affect the study evaluation
- Use of any investigational product and/or device within the 2 months prior to enrollment
- History of ketoacidosis or hyperosmolar hyperglycemic state during the previous 12 months prior to enrollment
- History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months prior to enrollment
- History of congestive heart failure
- History of hypoglycemia unawareness or unexplained hypoglycemia during the previous 12 months prior to enrollment
- Hemoglobinopathy or hemolytic anemia, transfusion of blood or plasma products within 3 months prior to enrollment
- Known hypersensitivity / intolerance to insulin glargine or any of its excipients
- History of pancreatitis
- Pregnant or breast-feeding women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method)
- Shift workers or those who regularly work a night-time shift
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: insulin glargine
Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day.
Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
|
Pharmaceutical form:solution Route of administration: subcutaneous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Responder rate (HbA1c levels <7%) without severe hypoglycemia
Time Frame: 24 weeks
|
24 weeks
|
Responder rate (HbA1c levels <6.5% and <7%)
Time Frame: 24 weeks
|
24 weeks
|
Changes of fasting plasma glucose (FPG) levels from baseline
Time Frame: 24 weeks
|
24 weeks
|
Changes of beta cell marker: C-peptide from baseline
Time Frame: 24 weeks
|
24 weeks
|
Changes of Lipid profile: Lipid profile from baseline
Time Frame: 24 weeks
|
24 weeks
|
Weight change from baseline
Time Frame: 24 weeks
|
24 weeks
|
Total insulin dose (per kg body weight)
Time Frame: 24 weeks
|
24 weeks
|
Evaluation of patient's treatment satisfaction
Time Frame: 24 weeks
|
24 weeks
|
Number of patients with hypoglycemia
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Number of patients with treatment-emergent adverse events
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
October 26, 2011
First Submitted That Met QC Criteria
October 27, 2011
First Posted (Estimate)
October 28, 2011
Study Record Updates
Last Update Posted (Estimate)
January 30, 2013
Last Update Submitted That Met QC Criteria
January 29, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LANTU_L_05477
- U1111-1118-8753 (Other Identifier: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on INSULIN GLARGINE HOE 901
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
-
SanofiCompleted
-
IRCCS San RaffaeleTerminatedType 2 Diabetes Mellitus | Peripheral Vascular DiseaseItaly
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
SanofiCompleted
-
Medical University of GrazCompletedDiabetes Mellitus, Type 2Austria
-
SanofiCompletedType 1 Diabetes MellitusUnited States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden